MEDI0457
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MEDI0457, covering 2022-08-25 to 2022-08-25. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer [Phase 1, Phase 2]